¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple sleep latency test2"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sleep-wake schedule disorder
    ¼ö¸é°¢¼ºÀÏÁ¤Àå¾Ö
  • sleep-wake transition disorder
    ¼ö¸é°¢¼ºÀÌÇàÀå¾Ö
  • slow wave sleep
    ´À¸°ÆÄÇü¼ö¸é, ¼­ÆÄ¼ö¸é(ßï÷îâ²Øù)
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ, À¯Àü´Ù¹ß¿Ü°ñÁõ
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù¼ö-, ´ÙÁß-, ´Ù-
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶À¯ÀüÀÚ, º¹¼ö´ë¸³À¯ÀüÀÚ
  • multiple birth
    ´Ùžƺи¸
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple endocrine adenomatosis
    ´Ù¹ß¼º³»ºÐºñ»ùÁ¾Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple stratification
    ¹µÁßÃþ
  • multiple trichoepithelioma
    ¿©·¯ÅлóÇÇÁ¾
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • multiple compressed tablet
    ´ÙÁß¾ÐÃà¾Ë¾à
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple layer tablet
    ´ÙÃþ¾Ë¾à
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple pressure method
    ´Ù¾Ð¹ý
  • multiple subpial transection
    ´Ù¹ß¿¬¸·¹ØÀý´Ü¼ú
  • multiple suture synostosis
    ´Ù¹ßºÀÇÕÀ¯ÂøÁõ
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • obstructive sleep apnea
    Æó¼â¼ö¸é¹«È£Èí
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • prolonged sleep therapy
    Áö¼Ó¼ö¸é¿ä¹ý, Àå±â¼ö¸é¿ä¹ý(íåÑ¢â²ØùèþÛö).
  • protracted sleep
    Áö¼Ó(¼º) ¼ö¸é(ÐüáÙàõâ²Øù).
  • shift work sleep disorder
    ±³´ë±Ù¹«¼ö¸éÀå¾Ö(º´)
  • sleep activation
    ¼ö¸éºÎȰ(¹ý)(¡­Ý¥üÀÛö) ³úÆÄ(Òà÷î)ÀÇ .
  • sleep apnea
    ¼ö¸é¹«È£ÈíÁõ(º´)
  • sleep apnea syndrome
    ¼ö¸é¹«È£ÈíÁõÈıº
  • sleep attacks
    ¼ö¸é¹ßÀÛ
  • sleep bruxism
    À̰¥ÀÌ
  • sleep choking syndrome
    ¼ö¸éÁú½ÄÁõÈıº
  • sleep deprivation
    ¼ö¸é¹æÇØ.
  • sleep diary
    ¼ö¸éÀϱâ
  • sleep disorder
    ¼ö¸éÀå¾Ö
  • sleep drunkenness
    ¼ö¸é¸íÁ¤.
  • sleep electroencephalography
    ¼ö¸é³úÆÄ
  • sleep enuresis
    ¾ß´¢Áõ(º´)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MLAEP middle latency auditory evoked potential
MLR mean length response; middle latency response; mixed lymphocyte reaction
MLT left mentotransverse [fetal position] [Lat. mento-laeva transversa]; mean latency time; median letha...
PML peripheral motor latency; polymorphonuclear leukocyte; posterior mitral leaflet; progressive multifo...
SL sarcolemma; sclerosing leukoencephalopathy; secondary leukemia; segment length; sensation level; sen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TFL Tail flick latency
DL distal latency
IPL inter peak latency
L latency
ML medium latency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple infection
    ´Ù¹ß¼º °¨¿°
  • multiple lentigines syndrome
    ´Ù¹ß¼º ÈæÀÚ ÁõÈıº
    »ó¿°»öü¼º ¿ì¼ºÀÇ À¯Àü¼º ÁõÈıºÀ¸·Î¼­ ´Ù¹ß¼º °ËÀº »ç¸¶±Í, ¹«ÁõÈıº¼º ½ÉÀå °áÇÔ. ƯÀÌÇÑ ¾ó±¼ ¸ð¾ç, Æóµ¿¸Æ ÇùÂø, Áö°¢ ½Å°æ¼º ³­Ã», °ñ°Ý ÀÌ»ó, ¾ç¾È °Ý¸®, ¼º±â ±âÇü µîÀ» ³ªÅ¸³½´Ù.
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾, ´Ù¹ß¼º ÇüÁú ¼¼Æ÷Á¾
    1. °ñ¼öÀÇ ¾Ç¼º ½Å»ý¹°. 2. ÇüÁú ¼¼Æ÷ Áúȯ±º Áß °¡Àå Áß¿äÇϰí ÈçÇÑ ÇüÅ·μ­ °ñ°Ý°è¿Í ¶§·Î ¿¬°ñ ºÎÀ§¿¡ ¼º¼÷ ¶Ç´Â ¹Ì¼º¼÷ ÇüÁú ¼¼Æ÷µéÀÌ ´Ù¹ß¼º Á¾±â¸¦ Çü¼ºÇÏ´Â °æ¿ìÀÌ´Ù. 3. ´Ù¹ß¼º °ñ¼öÁ¾Àº ³­Ä¡¼º ¾Ç¼º Ç÷¾× Á¾¾çÀÌ´Ù. ´Ù¸¥ Á¾¾çµé°ú ¸¶Âù°¡Áö·Î ¿øÀÎÀº ¸ð¸£¸ç ÁÖ¿ä Áõ»óÀ¸·Î´Â »ÀÀÇ ¾àÈ­, °ñÀý µîÀÌ °¡Àå ÈçÇϰí, ºóÇ÷, ½Å ºÎÀü, °¨¿° µîÀ¸·Î ³ªÅ¸³­´Ù. º´±â´Â 1, 2, 3±â·Î ³ª´©¸ç ´ë°³ 3±â¿¡ ÁÖ·Î ¹ß°ßµÇ³ª ±Ù·¡¿¡´Â °Ç°­ Áø´Ü µîÀ» ÅëÇØ Á¶±â¿¡ ¹ß°ßµÇ±âµµ ÇÑ´Ù. ´ëÁõÀûÀÎ Ä¡·á°¡ Áß¿äÇϸç Áúȯ ÀÚü¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·áÀÇ ¼ºÀûÀº ¸¸Á·½º·´Áö ¾Ê´Ù. Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº °æ¿ì´Â Æò±Õ ¼ö¸íÀÌ ¼ö°³¿ù¿¡ ºÒ°úÇϰí Ä¡·áÇÑ °æ¿ìÀÇ Æò±Õ ¼ö¸íÀº 3³â Á¤µµÀ̳ª 3±â¿¡¼­´Â 1³â ³»¿ÜÀÌ´Ù. 1990³â´ë¿¡ Ä¡·á ¹æ¹ýÀÌ ¹ß´ÞÇÏ¿© ÀÎÅÍÆä·Ð°ú °ñ¼ö À̽ÄÀÌ ¼Ò°³µÇ¾ú´Ù. ÀÎÅÍÆä·ÐÀº ȯÀÚÀÇ º´ÀÌ ¸¹ÀÌ °¨¼ÒÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÑ °æ¿ì Àç¹ßÀ» ´ÊÃß´Â È¿°ú°¡ °ËÁõµÇ¾ú´Ù. ȯÀÚÀÇ °ñ¼ö, ȤÀº ±ÙÀÚ¿¡´Â ¸»ÃÊÇ÷¾×ÀÇ Á¶Ç÷¸ð¼¼Æ÷¸¦ À̽ÄÇÏ°í °í¿ë·®ÀÇ Ç×¾Ï Ä¡·á¸¦ ÇÏ´Â ÀÚ°¡ ÀÌ½Ä Ä¡·á´Â ÇöÀç±îÁö Æò±Õ ¼ö¸íÀÌ 5³âÀÌ »óÀ¸·Î º¸°íµÇ¾î °ú°ÅÀÇ Ä¡·á¹ý°ú´Â ¿ùµîÇÑ Çâ»óÀ» º¸¿© Ȱ¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â ÀÚ°¡ À̽Ŀ¡¼­µµ ¾Ï ¼¼Æ÷°¡ ¾ø´Â Á¶Ç÷¸ð¼¼Æ÷¸¸À» ÃßÃâÇÏ¿© À̽ÄÇϴ ÷´ÜÀÇ Ä¡·á¹ýÀÌ ¼Ò°³µÇ°í ÀÖ¾î ¿ÏÄ¡¸¦ ÇâÇØ ÇÑ °ÉÀ½¾¿ ÁøÇàµÇ°í ÀÖ´Ù°í º¸¿©Áø´Ù. ´Ù¹ß¼º °ñ¼öÁ¾ÀÇ Áø´ÜÀº Southwest Oncology Grou
  • multiple myositis
    ´Ù¹ß ±Ù¿°, ´Ù¹ß¼º ±Ù¿°
  • multiple neurofibromatosis
    ´Ù¹ß ½Å°æ ¼¶À¯Á¾Áõ
  • multiple neuroma syndrome
    ´Ù¹ß¼º ½Å°æÁ¾ ÁõÈıº
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
  • multiple petechia
    ´Ù¹ß¼º Á¡»ó ÃâÇ÷
  • multiple photoreceptor
    ´Ù¹ß¼º ±¤ ¼ö¿ëü, ´Ù¹ß¼º ±¤ ¼ö¿ë±â
  • multiple projection
    ´Ù¹ß¼º Á¶»ç
  • multiple pulmonary emboli
    ´Ù¹ß¼º Æó »öÀü
  • multiple region
    ´Ù¹ß¼º ºÎÀ§
  • multiple rough gravellike sound
    ´Ù¹ß¼ºÀÇ °ÅÄ£ ÀÚ°¥ °¡´Â ¼Ò¸®
  • multiple seborrheic keratoses
    ´Ù¹ß Áö·ç¼º °¢È­Áõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
multiple alcohol An alcohol containing more than one OH group.
(05 Mar 2000)
multiple amputation Amputation of two or more limbs or parts of limbs performed at the same operation.
(05 Mar 2000)
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á